Eisai, Biogen’s Alzheimer’s candidate shows promise in PhII trial
At last some good news for Alzheimer’s research, as Eisai and Biogen’s experimental anti beta-amyloid therapy BAN2401 hit targets in a Phase II trial in patients with the disease.
Read More
